Description:
Minimal-residual disease (MRD) will be measured either by flow cytometry, or polymerase chain
reaction (PCR) methods, in 3 check-points and it will be one of the decision-making control
parameter for the optimal therapy tactics.
Patients with initially high-risk group and those with high MRD after 2 initial courses of
chemotherapy will be assigned to the allogenic transplantation of the hematopoietic stem
cells from Human Leucocyte Antigen (HLA) matched or haploidentical family donors.
Title
- Brief Title: A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML
- Official Title: A Prospective Multicenter Clinical Trial of Treatment Strategy Based on MRD Level After 2 Initial Courses of Chemotherapy in Children and Young Adults With Acute Myeloid Leukemia
Clinical Trial IDs
- ORG STUDY ID:
NCPHOI-2018-05
- NCT ID:
NCT03846362
Conditions
- Acute Myeloid Leukemia, Childhood
Purpose
Minimal-residual disease (MRD) will be measured either by flow cytometry, or polymerase chain
reaction (PCR) methods, in 3 check-points and it will be one of the decision-making control
parameter for the optimal therapy tactics.
Patients with initially high-risk group and those with high MRD after 2 initial courses of
chemotherapy will be assigned to the allogenic transplantation of the hematopoietic stem
cells from Human Leucocyte Antigen (HLA) matched or haploidentical family donors.
Detailed Description
Genetic alterations in acute myeloid leukemia (AML) clone are well known prognostic risk
factors of AML relapse. Standard risk group includes favorable t (15;17) (q22; q21) and inv
(16)/t (16;16). High-risk patients have a complex karyotype rearrangement (3 and more),
inversion of the long arm in 3rd chromosome and EVI1 gene rearrangement, monosomy 5 and 7,
translocations involving KMT2A gene and several rare translocations. All other genotype
alterations attributed to the moderate risk group.
Besides genetic factors, detection of the minimal residual disease (MRD) after initial
chemotherapy and its decrease rate after 1st postremission chemotherapy with high dose
Cytarabine and anthracyclines, plays a crucial role in the development of the morphologic
relapse. Patients with PCR-MRD<0,1% after 2 courses of chemotherapy have a 30% or less risk
of relapse, while PCR-MRD>0,1% - over 70%. In the clinical trial investigators are planning
to measure MRD either by immune-phenotype, or PCR methods, in 3 check-points and it will be
one of decision-making control parameter for the optimal therapy tactics.
Patients with initially high-risk group and those with high MRD after 2 initial courses of
chemotherapy will be assigned to the allogenic transplantation of the hematopoietic stem
cells from HLA- matched or haploidentical family donors.
Trial Arms
Name | Type | Description | Interventions |
---|
intermediate risk MRD2>0,1% | Experimental | MRD2>0,1% - FLA - MRD3 - HSCT | |
Eligibility Criteria
Inclusion Criteria:
1. de novo acute myeloid leukemia
2. signed informed consent
Exclusion Criteria:
diagnosis of: Fanconi anemia, acute promyelocytic leukemia, MDS, JMML, AML as secondary
malignancy, Dawn syndrome.
Maximum Eligible Age: | 18 Years |
Minimum Eligible Age: | N/A |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | relapse-free survival (RFS) |
Time Frame: | 1 year |
Safety Issue: | |
Description: | relapse-free survival from date of diagnosis till date of relapse, or date of death (whichever comes first) or date of last follow up |
Secondary Outcome Measures
Measure: | overall survival (OS) |
Time Frame: | 1 year |
Safety Issue: | |
Description: | |
Measure: | event-free survival (EFS) |
Time Frame: | 2 years |
Safety Issue: | |
Description: | Event=relapse/nonresponse, death or second malignancy |
Measure: | The proportion of of patients with severe adverse effects |
Time Frame: | 6 months |
Safety Issue: | |
Description: | The proportion of of patients with severe adverse effects of therapy according to CTCAE (ver 4.3) |
Measure: | The proportion of of patients with severe infections |
Time Frame: | 1 month |
Safety Issue: | |
Description: | The proportion of of patients with severe infections: number of episodes, grade, after each course of chemotherapy |
Measure: | The proportion of of patients with severe cardiotoxicity |
Time Frame: | 1 year |
Safety Issue: | |
Description: | The proportion of of patients with severe cardiotoxicity: number of episodes and %EF by echocardiogam |
Measure: | MRD dynamic |
Time Frame: | 1 months |
Safety Issue: | |
Description: | MRD (IFT and/or PCR) dynamic between check-points |
Measure: | MRD specificity and sensitivity |
Time Frame: | 1, 2, 3 months |
Safety Issue: | |
Description: | MRD specificity and sensitivity in relapse prognosis |
Measure: | Cumulative incidence of relapse |
Time Frame: | 6 months, 1 year |
Safety Issue: | |
Description: | competing event - death in CR |
Measure: | Cumulative incidence of transplant-related mortality |
Time Frame: | 6 months after HSCT |
Safety Issue: | |
Description: | for transplanted patients |
Measure: | Cumulative incidence of aGvHD II-IV grade |
Time Frame: | 100 days after HSCT |
Safety Issue: | |
Description: | for transplanted patients |
Measure: | Cumulative incidence of cGvHD |
Time Frame: | 1 year after HSCT |
Safety Issue: | |
Description: | for transplanted patients |
Details
Phase: | Phase 3 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
Trial Keywords
- AML
- MRD
- stem cell transplantation
- pediatric
- leukemia
- haploidentical
- TcRab-depletion
- young adult
Last Updated
May 1, 2019